Sisram Medical Full Year 2023 Earnings: EPS: US$0.067 (vs US$0.086 in FY 2022)

Sisram Medical (HKG:1696) Full Year 2023 Results

Key Financial Results

• Revenue: US$359.3m (up 1.4% from FY 2022).
• Net income: US$31.5m (down 22% from FY 2022).
• Profit margin: 8.8% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: US$0.067 (down from US$0.086 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sisram Medical Earnings Insights

The primary driver behind last 12 months revenue was the North America segment contributing a total revenue of US$156.9m (44% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$125.3m (67% of total expenses). Explore how 1696's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 13% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Sisram Medical that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.